Related Experiment Video
Updated: Dec 27, 2025
05:25
Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
Published on: December 29, 2021
2.8K
Epilepsy and cannabidiol: a guide to treatment
Alexis Arzimanoglou1, Ulrich Brandl2, J Helen Cross3
1Paediatric Epilepsy Dpt., University Hospitals of Lyon (HCL), Member of the ERN EpiCARE, and Inserm U1028/CNRS UMR5292, Lyon, France
Epileptic Disorders : International Epilepsy Journal with Videotape
|February 26, 2020
Summary
Pure cannabidiol (CBD) shows therapeutic value for epilepsy, supported by recent evidence. However, the market lacks standardization for CBD products, impacting their effectiveness and safety for patients.
Area of Science:
- Pharmacology and Neurology
- Cannabinoid Therapeutics
- Epilepsy Treatment
Background:
- Growing interest in cannabidiol (CBD) for epilepsy treatment.
- Recent legislative changes reflect this growing interest.
- Emergence of a wide range of CBD products on the market.
Purpose of the Study:
- To review the therapeutic value of purified CBD products for intractable epilepsy.
- To inform neurologists and epileptologists about CBD's role in routine practice.
- To address the lack of consensus and standardization in CBD product preparation and composition.
Main Methods:
- Review of placebo-controlled randomized controlled trials (RCTs).
- Analysis of Class I evidence for purified CBD.
- Focus on patients with Lennox-Gastaut syndrome and Dravet syndrome.
Main Results:
- Class I evidence now available for purified CBD in specific epilepsy syndromes.
- Significant variability in purity, preparation, and concentration of market CBD products.
- Lack of standardization hinders understanding of product effectiveness.
Conclusions:
- Purified CBD demonstrates therapeutic potential for specific epilepsy types.
- Neurologists need clear guidance on using CBD products in clinical practice.
- Urgent need for standardization in the CBD product market to ensure patient safety and treatment efficacy.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
544
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
544
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
01:08Antiepileptic Drugs: Sodium Channel Blockers
1.5K
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1.5K
01:13Seizures: Classification
1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
741
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
741